News Highlights
  • Norwich announces major investment

    Norwich Pharmaceuticals (“Norwich”) is excited to announce a recent decision by its parent organization (Alvogen) to provide major capital investment in Plant and equipment. Starting immediately, there will be a projected investment of $26 million over the next two years, focused on increasing manufacturing capacity.


Our portfolio is focused on high value difficult to make formulations for the U.S. market.

Read more


Norwich Pharmaceutical Services in upstate New York, is Alvogen‘s U.S. manufacturing base.

Read more

Alvogen in brief

Alvogen is a multinational, privately-owned pharmaceuticals company, focused on complex generic pharmaceutical products.

Read more


Our values represent the behaviors and attitudes needed to fulfill and reinforce our purpose and guide our day-to-day decision making.

Read more

Stay Connected

Would you like to learn more about Alvogen, like to interview our management or get more information on our business activities? We would like to hear from you.